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Wioletta Szeszel-Fedorowicz, Indrani Talukdar, Brian N. Griffith, Callee M. Walsh, and Lisa M. Salati1
From the Department of Biochemistry and Molecular Pharmacology, West Virginia University, Morgantown, West Virginia 26506
The inhibition of glucose-6-phosphate dehydrogenase (G6PD)
expression by arachidonic acid occurs by changes in the rate
of pre-mRNA splicing. Here, we have identified a cis-acting
RNA element required for regulated splicing of G6PD mRNA.
Using transfection of G6PD RNA reporter constructs into rat
hepatocytes, the cis-acting RNA element involved in this regulation was localized to nucleotides 43–72 of exon 12 in the G6PD
mRNA. In in vitro splicing assays, RNA substrates containing
exon 12 were not spliced. In contrast, RNA substrates containing other regions (exons 8 and 9 or exons 10 and 11) of the G6PD
mRNA were efficiently spliced. Furthermore, exon 12 can
inhibit splicing when substituted for other exons in RNA substrates that are readily spliced. This activity of the exon 12 regulatory element suggests that it is an exonic splicing silencer.
Consistent with its activity as a splicing silencer, spliceosome
assembly was inhibited on RNA substrates containing exon 12
compared with RNAs representing other regions of the G6PD
transcript. Elimination of nucleotides 43–72 of exon 12 did not
restore splicing of exon 12-containing RNA; thus, the 30-nucleotide element may not be exclusively a silencer. The binding of
heterogeneous nuclear ribonucleoproteins K, L, and A2/B1
from both HeLa and hepatocyte nuclear extracts to the element
further supports its activity as a silencer. In addition, SR proteins bind to the element, consistent with the presence of
enhancer activity within this sequence. Thus, an exonic splicing
silencer is involved in the inhibition of splicing of a constitutively spliced exon in the G6PD mRNA.

Glucose-6-phosphate dehydrogenase (G6PD)2 is a member
of a family of enzymes that catalyze the de novo synthesis of
fatty acids. In liver, the lipogenic pathway plays an essential role
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in converting excess dietary energy into a storage form. Consistent with this role in energy homeostasis, the capacity of this
pathway is regulated by dietary changes, such as fasting, feeding, and the amount and type of carbohydrate and polyunsaturated fat in the diet (1). For many of the lipogenic enzymes,
regulation of enzyme amount occurs primarily by changes in
the transcription rate of the gene, but posttranscriptional regulation via mRNA stability has also been implicated (1). G6PD
differs from the other family members in that dietary regulation
occurs exclusively at a posttranscriptional step (2– 4).
G6PD expression is inhibited by polyunsaturated fatty
acids, such as arachidonic acid; this occurs at a unique posttranscriptional step involving a decrease in the rate of splicing of the nascent G6PD transcript. Several lines of evidence
indicate that changes in mature mRNA accumulation are
caused by changes in the efficiency of splicing of the G6PD
transcript. First, changes in the cytoplasmic accumulation of
G6PD mRNA are preceded by changes in the accumulation
of mRNA in the nucleus in the absence of changes in transcriptional activity of the gene (3–5). Second, stimulatory
treatments, such as refeeding, enhance the rate of accumulation of partially and fully spliced G6PD mRNA with little or
no change in abundance of the primary transcript (2). Third,
inhibition of G6PD expression by polyunsaturated fat results
in an accumulation of partially spliced mRNA in the nucleus
despite a decrease in the nuclear content of mature mRNA
(6). Finally, using transient transfection of RNA reporter
constructs containing progressive deletion of the 13 exons of
the G6PD precursor mRNA (pre-mRNA) into rat hepatocytes, we have demonstrated that exon 12 and its surrounding introns are necessary for the arachidonic acid inhibition
of mRNA accumulation (6). Thus, we conclude that G6PD
expression is regulated by changes in the rate of pre-mRNA
splicing.
This mechanism of regulation of G6PD by inhibition of its
splicing may be shared across other metabolic genes, even those
regulated by transcriptional mechanisms. In this regard, nutritional status regulates expression of the tricarboxylate (citrate)
carrier and spot 14, a putative lipogenic protein by a nuclear
posttranscriptional mechanism (2, 7–9). Regulation of accumulation of spliced intermediates has been observed for these
genes, but the molecular details are not known. Regulating gene
expression by changes in the rate of pre-mRNA splicing in addition to transcriptional regulation would result in a more rapid
response to nutritional or hormonal changes.
Pre-mRNA splicing results in the removal of introns from
primary transcripts and the joining of the exons containing
the protein coding information. The G6PD gene is over 18
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kb, and all of its exons are constitutively spliced. Exons can
be constitutively or alternatively spliced. Constitutively
spliced exons are those always present in the mRNA and
account for the majority of exons. The alternative splicing of
mRNA transcripts, which occurs for at least 60% of all genes,
results in the production of different proteins and can occur
in a tissue- or treatment-specific manner (10). Both constitutive and alternative splicing requires distinguishing exons
from the surrounding intronic RNA. Exon definition, as the
process of exon recognition is called, utilizes intronic
sequences, which include the 5⬘ and 3⬘ splice sites, polypyrimidine tract, and branch point, as well as sequence elements in the exon called exonic splicing enhancers (ESEs)
(11). ESEs are not highly conserved with respect to sequence
and thus must be functionally characterized in the
pre-mRNA (12, 13). The activity of ESEs involves their binding by members of a family of splicing regulatory proteins,
serine/arginine-rich (SR) proteins (14). SR proteins participate in splicing by enhancing the recruitment of the key
spliceosome components, U1 small nuclear ribonucleoprotein particle (snRNP) and U2 snRNP (11). In the absence of
an ESE, binding of U1 and U2 snRNPs to the 5⬘ splice site and
branch point, respectively, is less stable, and the rate of complex formation is slowed (11, 15).
Pre-mRNA splicing can also be inhibited by the action of
silencer elements in the RNA. These sequences are present
in both introns and exons and are bound by a diverse group
of proteins that include some members of the heterogeneous
nuclear ribonucleoprotein (hnRNP) family of proteins (16 –
19). Like enhancer elements, silencers exhibit great sequence
diversity, and their identification in mRNA requires functional tests for their activity (19 –21). When the silencer is
present in the intron, it functions to suppress recognition of
the splice sites; this is a key mechanism in alternative splicing
(10). In contrast, exonic splicing silencers (ESSs) suppress
exon definition, which involves interference with the binding of a splicing co-activator (22–24). In this regard, the
juxtaposition of ESS and ESE elements in an exon results in
the mutually exclusive binding of hnRNPs versus SR proteins
(cf. Refs. 23 and 24). Although the role of ESSs in regulating
splicing is best understood in alternative splicing, computational approaches suggest that ESSs are also present in constitutively spliced exons (21). The molecular details by which
ESSs can regulate the splicing of constitutive exons remain
largely unexplored.
G6PD mRNA is not alternatively spliced; thus, the regulation
of its splicing by nutritional factors involves changes in the rate
of splicing of a constitutively spliced exon. Understanding the
molecular details by which G6PD pre-mRNA splicing is regulated will provide novel information on the mechanisms by
which cells can regulate the rate of constitutive splicing and the
role this process can play in controlling gene expression. In the
present report, we identify the splicing regulatory element
involved in the inhibition of G6PD pre-mRNA splicing by polyunsaturated fatty acids. This 30-nt regulatory element contains
an ESS. The ESS can block the splicing of heterologous introns
in an in vitro splicing assay. Consistent with its activity as a
silencer, the exon 12 element inhibits spliceosome assembly by
NOVEMBER 10, 2006 • VOLUME 281 • NUMBER 45

attenuating the formation of the first ATP-requiring complex
in this process and binds hnRNPs, associated with inhibition of
splicing. This is the first report of an ESS in a constitutively
spliced exon being involved in the regulation of gene
expression.

EXPERIMENTAL PROCEDURES
Animal Care and Cell Culture—Male Sprague-Dawley rats
(175–250 g) were fed a chow diet and then starved 16 h prior to
hepatocyte isolation. Hepatocytes were isolated by a modification of the Seglen technique (25) as described previously (4).
Hepatocytes (3.1 ⫻ 106) were placed in 60-mm dishes coated
with rat tail collagen and incubated in Hi/Wo/BA medium
(Waymouth MB752/l plus 20 mM Hepes, pH 7.4, 0.5 mM serine,
0.5 mM alanine, 0.2% bovine serum albumin) plus 5% newborn
calf serum (37 °C, 5% CO2). Cell viability in all experiments was
90% or greater as estimated by trypan blue (0.04%) exclusion.
After 3– 4 h, the medium was replaced with serum-free
medium, and the constructs presented in Figs. 1 and 2 were
transfected. Each construct (2.5 g/plate) was transfected using
Lipofectin according to the manufacturer’s protocol (Invitrogen). The ratio of DNA to liposome reagent was 1:6.7. A Matrigel overlay (0.3 mg/ml; BD Pharmingen) was added to hepatocytes 4 h after the transfection was begun (26). The transfection
medium remained on the hepatocytes for 16 h and then was
replaced with medium containing the treatments indicated in
the figure legends. Subsequently, the medium was changed
every 12 h to one of the same composition. Arachidonic acid
(Nu-Check Prep, West Elysian, MN) was bound to bovine
serum albumin (27). The fatty acid (4 mM)/albumin (1 mM)
stock contained butylated hydroxytoluene (0.01%), and the
medium contained ␣-tocopherol phosphate, disodium (10
g/liter), to minimize oxidation of the fatty acids.
Construction of RNA Reporter Plasmids and Templates for
the in Vitro Splicing Assay—Plasmids used in the analysis of
cis-acting elements in the G6PD primary transcript were made
using pGL3-Basic (Promega Corp.) as the vector backbone. The
luciferase gene was removed from this vector, and portions of
G6PD genomic DNA and the cytomegalovirus (CMV) promoter/enhancer sequences (1– 640 bp from the pCMV␤ vector;
Clontech) were inserted into the multiple cloning site. Mutated
RNA reporter constructs were prepared by replacing the G6PD
sequence indicated in the legend to Fig. 2 with the sequence
AAGCATGCAA using overlap extension PCR (28). The plasmid p␤gal ex12-ex13 was made by replacing luciferase with the
␤-galactosidase gene from pCMV␤. G6PD sequences from
nucleotide 37 of exon 12 through the end of the gene were
ligated into ␤-galactosidase, deleting the terminal 13 amino
acids of the ␤-galactosidase protein. The p␤gal in12-ex13 plasmid deletes all but the last 8 nt of exon 12 to maintain the
5⬘-splice site. All sequences were evaluated to ensure that premature termination codons did not arise during cloning. Templates (Fig. 3A) for preparing in vitro splicing substrates were
synthesized by PCR using either wild type G6PD sequences or
the mutated sequences described above as templates. The T3
promoter was introduced by PCR upstream of the first exon in
the substrate, and the PCR products were used in the in vitro
transcription reactions. The templates for the chimeric splicing
JOURNAL OF BIOLOGICAL CHEMISTRY
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substrates (Fig. 3C) were generated using overlap extension
PCR and cloned downstream of a T7 promoter in pKS⫹ (Stratagene). These plasmids were linearized with XbaI prior to in
vitro transcription of the RNA. The template for the ␤-globin in
vitro splicing substrate (pSP64-H␤␦6) was obtained from Dr.
Adrian Krainer (29).
Isolation of Total RNA and Ribonuclease Protection Assay—
Total RNA from three plates per treatment was isolated by the
method of Chomczynski and Sacchi (30). Quantitation of transgene and endogenous mRNA was conducted using RNase protection assays (Ambion, Inc.) as previously described (6). ␤-Actin mRNA was used as a loading control. The template for rat
␤-actin was purchased from Ambion, Inc. The resulting hybridization products protected from RNase digestion were separated in a 6% (7 M urea) polyacrylamide gel. Images were visualized by storage phosphorimaging and quantified using
ImageQuant software (Amersham Biosciences).
In Vitro Splicing Assay—In vitro splicing substrates were synthesized by in vitro transcription of the G6PD minigenes with
T7 or T3 polymerase using [32P]CTP. HeLa cell nuclear extract
was purchased from Promega or prepared as previously
described (31) with packed HeLa S3 cells from the National Cell
Culture Center. Splicing assays were performed in 20-l reaction volumes containing 10 –20 ng of 32P-labeled in vitro splicing substrate, 40% (v/v) nuclear extract, 20 mM Hepes, pH 7.4,
0.5 mM ATP, 20 mM creatine phosphate, 3 mM MgCl2, and 2.5%
polyvinyl alcohol. Reactions were incubated for 4 h unless otherwise stated in the figure legends. Reactions were stopped by
the addition of 200 l of stop-splicing solution (0.3 M sodium
acetate, pH 5.2, 0.1% (w/v) SDS, 62.5 g/ml tRNA) (32). RNA
was purified from the splicing mixture with Tris-HCl-saturated
phenol (pH 8.0) followed by precipitation with ethanol. Splicing
products were analyzed on 6% denaturing polyacrylamide gels
and visualized by storage phosphorimaging. Quantification of
splicing reactions in Fig. 4B was performed as follows. Radioactive bands corresponding to the spliced products and unspliced
in vitro splicing substrates were quantified with ImageQuant.
These values were corrected with respect to the number of
cytosines in each band and are referred to as normalized PhosphorImager units. The percentage of spliced mRNA was calculated as the ratio of the normalized PhosphorImager units of
spliced mRNA divided by the sum of the amounts of unspliced
plus spliced RNA. Statistical analysis of spliced product accumulation used one-way analysis of variance and least squares fit
(33).
Spliceosome Assembly and Gel Electrophoresis—Analysis of
spliceosome complex formation was conducted by incubating the RNA substrates in the splicing conditions described
above. At the time points indicated in Fig. 5, heparin (0.2
mg/ml) was added to the splicing mixture. After incubation
for an additional 5 min at 30 °C, the samples were placed on
ice, and 5 l of each reaction was fractionated on a native 4%
polyacrylamide gel (acrylamide/bisacrylamide, 80:1), using
200 V at room temperature for 3 h (34). For agarose gel
electrophoresis, in vitro splicing mixtures were incubated
without heparin and were placed on ice at the indicated time
points (Fig. 6). The complexes (5 l of each reaction) were
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separated using electrophoresis in 1.5% low melting point
agarose at 70 V for 3 h (35).
UV Cross-linking Assay—UV cross-linking was preformed
as described (36). The reaction mixtures contained 5 g of
nuclear extract protein and 10 –20 fmol of substrate RNA
(50,000 –100,000 cpm). Binding of proteins to the RNA was
visualized using storage phosphorimaging and quantified
using ImageQuant.
RNA Affinity Assay—RNA oligomers were covalently linked
to adipic acid dihydrazide-agarose beads (37, 38). Briefly, 1000
pmol of RNA in a 400-l reaction mixture containing 100 mM
sodium acetate, pH 5.0, and 5 mM sodium m-periodate was
incubated for 1 h in the dark at room temperature. The RNA
was ethanol-precipitated and resuspended in 500 l of 0.1 M
sodium acetate, pH 5.0. Adipic acid dihydrazide-agarose beads
(400 l; Sigma) were washed four times in 10 ml of 0.1 M sodium
acetate, pH 5.0, and then mixed with the periodate-treated
RNA. The beads with the bound RNA were washed three times
with 2 M NaCl and three times with 20 mM HEPES-KOH, pH
7.6, 10% (v/v) glycerol, 150 mM KCl, 0.2 mM EDTA, and 200
g/ml tRNA. The RNA-bound beads were incubated with
100 –250 g of nuclear extracts in buffer (20 mM HEPES-KOH,
pH 7.6, 10% (v/v) glycerol, 150 mM KCl, 0.2 mM EDTA) plus 2.5
mM ATP, 2.0 mM MgCl2, 1000 ng/ml tRNA. Beads were then
washed four times with 1 ml of buffer. After the final centrifugation, the proteins bound to the immobilized RNA were eluted
in 80 mM Tris-Cl, pH 6.8, 0.1 M dithiothreitol, 2% SDS, 10%
glycerol, and 0.2% bromphenol blue for LC-MS/MS and in 1 M
Tris, pH 7.0, 10% SDS, 50% glycerol, and 0.1% bromphenol blue
for Western analysis by heating for 5 min at 95 °C.
LC-MS/MS and Western Analysis—Proteins eluted from the
RNA-linked beads were separated by size in a 10% polyacrylamide gel. The protein bands of interest were visualized by colloidal Coomassie Blue (Invitrogen) and excised from the gels.
The gel slices were digested with trypsin (2 g/ml) overnight at
37 °C. The digests were dried and reconstituted in 5% acetonitrile, 0.1% formic acid and then loaded onto a C18 column using
a helium pressure cell. Protein peptides were eluted from the
column using a linear acetonitrile gradient of 5–50% over 60
min with a flow rate 300 nl/min. The ion trap mass spectrometer (ProteomeX Work station) was programmed to perform a
full MS scan followed by MS/MS scans of the five most abundant ions present. Raw data files were compared with the
SwissProt data base using SEQUEST software to identify proteins that match the peptide fragments. SEQUEST results were
manually confirmed using the criteria described (39). Peptides
were accepted if they had a cross-correlation (Xcorr) score of at
least 1.9, 2.2, or 3.7 for the ⫹1, ⫹2, or ⫹3 charge states, respectively. Western analysis was as previously described (40). The
hnRNP antibodies (Immuquest) and SR antibodies (Zymed
Laboratories Inc.) were purchased from the indicated sources.

RESULTS
The Cis-acting RNA Element Involved in the Inhibition of
G6PD Expression in Rat Hepatocytes by Arachidonic Acid Is
Located between Nucleotides 43 and 72 of Exon 12—Incubation
of primary rat hepatocytes with insulin induces expression of
G6PD, whereas the addition of arachidonic acid inhibits G6PD
VOLUME 281 • NUMBER 45 • NOVEMBER 10, 2006
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FIGURE 1. The cis-acting element involved in splicing inhibition of G6PD pre-mRNA by arachidonic acid is localized in exon 12. Primary rat hepatocytes
were transfected with the pre-mRNA reporters shown in the figure. Each pre-mRNA reporter contains the CMV promoter to drive its transcription. The black
rectangles represent exons of the G6PD gene, striped rectangles represent the 3⬘-untranslated region of G6PD, and gray rectangles represent the ␤-galactosidase gene. SS, the presence of the 5⬘ splice site of intron 12 in this construct. After treatment with insulin (0.04 M) or insulin plus arachidonic acid (175 M) for
24 h, total RNA was isolated, and reporter and endogenous mRNA were measured using RNase protection assays. A, a representative RNase protection assay
is shown. B, the results are the mean ⫾ S.E. of multiple experiments (separate hepatocyte isolations). The repetition is as follows: n ⫽ 8 or more experiments for
pCMV in6-ex13 and pCMV ex12-ex13; n ⫽ 4 for pCMV SS-in12-ex13; n ⫽ 3 for p␤gal ex12-13, p␤gal in12-ex13, and pCMV in6-ex11,ex13; and n ⫽ 2 for pCMV
in6-ex11,in12,ex13. G6PD and reporter mRNAs were normalized to the amount of ␤-actin mRNA. The percentage inhibition by arachidonic acid for the
pre-mRNA reporters and for the endogenous gene was calculated by dividing the amount of G6PD mRNA in cells treated with insulin and arachidonic acid by
the amount in cells treated with insulin alone. FA, arachidonic acid.

expression (4). This decrease in G6PD mRNA accumulation
is similar to the decrease observed in livers isolated from
mice fed a high fat diet (rich in polyunsaturated fatty acids)
versus in livers isolated from mice fed a low fat diet (3).
Regulation of the G6PD gene in intact animals and in primary rat hepatocytes involves a decrease in the efficiency of
splicing of G6PD transcripts (2, 6). Because treating rat
hepatocytes with arachidonic acid mimics the effect of a high
fat diet, we used rat hepatocytes to localize the cis-acting
RNA element in the mouse G6PD transcript that is responsible for its splicing regulation. Exon 13 sequences differ
between rats and mice. Thus, ribonuclease protection assays
using exon 13 riboprobes are able to distinguish between the
endogenous rat mRNA and the mRNA produced from a
transfected reporter construct that expresses mouse G6PD
genomic DNA (6). These transient transfection assays do not
use co-transfection to correct for transfection efficiency,
NOVEMBER 10, 2006 • VOLUME 281 • NUMBER 45

because the presence of two viral promoters within the cells
increases variability in the data. Instead, the experiments are
replicated multiple times to account for differences in transfection efficiency. Furthermore, in our hands, variation in
transfection efficiency between treatments (insulin versus
insulin plus arachidonic acid) is less that 10% (data not
shown). In these reporter assays, arachidonic acid inhibited
the accumulation of mRNA from G6PD RNA reporters containing exon 12 to a similar extent as the endogenous gene
(Fig. 1) (6). Deletion of sequences 5⬘ of intron 12 abolished
the inhibition by arachidonic acid (Fig. 1; pCMV SS-in12ex13). To confirm that exon 12 contains a regulatory element, we used two approaches. First, exon 12 was deleted
from the G6PD reporter construct (pCMV in6-ex11,ex13
and pCMV in6-ex11,in12,ex13). Accumulation of mRNA
from these reporter constructs was not inhibited by arachidonic acid, whereas inhibition of the endogenous gene was
JOURNAL OF BIOLOGICAL CHEMISTRY
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observed as expected (Fig. 1). In the second approach, we
tested the ability of exon 12 to regulate the accumulation of
a heterologous mRNA. The ␤-galactosidase gene is not regulated by arachidonic acid in rat hepatocytes (data not
shown). Sequences from the last 56 nt of exon 12 through the
3⬘-UTR of the G6PD gene were ligated to the ␤-galactosidase
gene (p␤gal ex12-ex13). Accumulation of mRNA from this
construct was inhibited by arachidonic acid; however, deletion of exon 12 while maintaining the 5⬘ splice site of intron
12 (p␤gal in12-ex13) eliminates inhibition by arachidonic
acid (Fig. 1). Thus, a cis-acting RNA element involved in
inhibition of G6PD mRNA accumulation by arachidonic
acid is localized in the last 56 nt of exon 12, and this region of
exon 12 can regulate expression of a heterologous gene.
To localize the cis-acting element in exon 12, we performed
scanning mutagenesis across the exon. 10-nt-long block mutations were made across exon 12 in the context of pre-mRNA
reporter pCMV in6-ex13 (Fig. 2A, labeled 1–9). Exon 12 is 93 nt
long. The first two nucleotides at the 5⬘-end and the last nucleotide at the 3⬘-end were not mutated so as not to disrupt normal
splice site recognition. Each block mutation has the sequence
AAGCATGCAA. This sequence does not generate in-frame
stop codons, which induce nonsense-mediated decay (41). In
addition, we screened this sequence to find ESEs (available on
the World Wide Web at exon.cshl.edu/ESE) (42) and ESSs
(available on the World Wide Web at genes.mit.edu/fas-ess
(19) and cubweb.biology.columbia.edu/pesx (21); it did not
have a high score as a known splicing enhancer or silencer.
Mutation of sequences between nucleotides 43 and 72 of exon
12 (mutations 5–7) abrogated the inhibition of reporter mRNA
accumulation by arachidonic acid (Fig. 2B). For all other mutations, the accumulation of mRNA was inhibited to a similar
extent as the endogenous G6PD mRNA. In all transfected cells,
the amount of endogenous G6PD mRNA was decreased about
40% or more by arachidonic acid (data not shown). Thus, the
sequences of nucleotides 1– 42 and 73–93 were not required for
regulated splicing. To better define the region containing the
regulatory sequence, two additional reporter constructs were
produced. These RNA reporters contained 15-nt block mutations from nucleotides 33– 47 and 67– 82 in exon 12. These
mutations also abrogated regulation by arachidonic acid, highlighting the regulatory importance of the first and last five
nucleotides in the 43–72 regulatory region in exon 12.
Exon 12 Inhibits Splicing of Intron 11 in Vitro and Is Also Able
to Inhibit Splicing of Other Introns of G6PD—Our next question
concerned the activity of this element. Is it an ESS and/or an
ESE? These elements do not have true consensus sequences and
can vary both in sequence and length of the element and must
be functionally characterized (17, 19, 21, 42). Splicing regulatory sequences have the same activity in vivo and in vitro (31);
thus, we used the in vitro splicing assay to define the basal activity of the exon 12 regulatory element. The large amount of
ribonucleases in rat hepatocyte nuclear extract (43) precluded
its use in the splicing assay. HeLa cell nuclear extract is commonly used for in vitro splicing assays and is known to recapitulate splicing activity of various mammalian cell lines (cf. Refs.
16 and 31). We compared splicing between three different
G6PD in vitro splicing substrates: IVS 8-9, IVS 10-11, and IVS
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FIGURE 2. The splicing regulatory element in exon 12 is located between
nucleotides 42 and 73. A, structure of the mutated pre-mRNA reporters.
Black rectangles represent the exons of the G6PD gene, black lines represent
the introns, and the gray rectangles represent the 3⬘-untranslated region of
G6PD. The CMV promoter drove transcription of the reporters. The lines below
exon 12 indicate the mutations. Each mutation contains the indicated
sequence in place of the sequence at the following locations: mutation 1,
positions 3–12; mutation 2, positions 13–22; mutation 3, positions 23–32;
mutation 4, positions 33– 42; mutation 5, positions 43–52; mutation 6, positions 53– 62; mutation 7, positions 63–72; mutation 8, positions 73– 82; mutation 9, positions 83–92. B, quantification of reporter G6PD RNA. Transfection,
treatment with insulin (0.04 M) with or without arachidonic acid (175 M),
and RNA assay was as in Fig. 1. The percentage of inhibition by arachidonic
acid for the pre-mRNA reporters was calculated by dividing the amount of
G6PD mRNA in cells treated with arachidonic acid by the amount in cells not
incubated with arachidonic acid. All values were normalized by amount of
␤-actin mRNA to correct for differences in total RNA amount. Each bar shows
the mean ⫾ S.E. for at least n ⫽ 3 separate hepatocyte isolations (mutation 1,
n ⫽ 3; mutations 6 and 7, n ⫽ 4; mutations 2, 6, and 7, n ⫽ 6; mutations 3, 5, 8,
and 9, n ⫽ 7; mutation 4, n ⫽ 9). C, sequence of exon 12 from nucleotides
42–73 of the mouse G6PD mRNA.

11-12 (Fig. 3A). These substrates contain the entire exons and
intervening introns present in mouse G6PD RNA. IVS 8-9 and
IVS 10-11 were efficiently spliced in HeLa nuclear extract. In
contrast, a spliced product for IVS 11-12 was either undetectable or present at less than 5% of the total RNA as compared
with the 60 –70% rate of splicing for IVS 8-9 or IVS 10-11 (Figs.
3B and 4B). Splicing of IVS 11-12 was enhanced neither by
increasing the incubation time of the assay to 6 h nor by varying
the components of the assay (data not shown).
Several reasons may explain the lack of splicing of IVS 11-12.
First, exon 12 per se may inhibit splicing in vitro. Second, intron
11 may be difficult to splice in vitro. Third, the in vitro splicing
substrate IVS 11-12 may have been constructed in such a way
that it could not be spliced. Since IVS 10-11 was efficiently
spliced in vitro, we ruled out a negative effect of exon 11 on IVS
VOLUME 281 • NUMBER 45 • NOVEMBER 10, 2006
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FIGURE 3. Exon 12 inhibits splicing of different G6PD introns in vitro. A, schematic of G6PD in vitro splicing
substrates with their calculated sizes and the sizes of their spliced products. Boxes represent the exons, and
lines represent the introns of the G6PD gene. B, in vitro splicing assay. The in vitro splicing substrates were
incubated in splicing reactions for 60 min, and the substrates and products were resolved by denaturing
polyacrylamide gel electrophoresis. The identity of each band is indicated on the right side of the gels. Representative gels are shown; repetition was as follows: IVS 8-9 (n ⫽ 15), IVS 10-11 (n ⫽ 8), and IVS 11-12 (n ⫽ 12). C,
schematic of chimeric splicing substrates containing intron 11 in place of intron 10 in IVS 10,11,11, and exon 12
in place of the correct exon in IVS 10,10,12 and IVS 8,8,12. Exons and introns that were inserted to modify the
in vitro splicing substrates are shown in italic boldface type. D, splicing of chimeric substrates in the in vitro assay.
The splicing substrates and products were resolved with denaturing polyacrylamide gel electrophoresis, and
the identity of each band is indicated by the schematic. All splicing reactions were incubated for 240 min.
Representative gels are shown; repetition was as follows: IVS 10,11,11 (n ⫽ 7), IVS 10,10,12 (n ⫽ 6), IVS 8,8,12
(n ⫽ 4). In all cases, the molecular weight marker (M) was moved closer to the data lane for clarity. In two cases,
the reactions were run on the same gel, and the M lane was reproduced for clarity.
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11-12 splicing. To determine if
intron 11 or exon 12 are responsible
for the absence of splicing of IVS
11-12, we tested splicing of three
additional in vitro splicing substrates (Fig. 3C). In the first substrate (IVS 10,11,11), intron 10 was
replaced by intron 11 within the
context of the efficiently spliced
substrate IVS 10-11. IVS 10,11,11
was efficiently spliced in the in vitro
assay (Fig. 3D). We next replaced
exons 9 and 11 with exon 12 in the
context of IVS 8-9 and IVS 10-11,
respectively. Splicing was not
observed for these chimeric substrates containing exon 12 (Fig. 3D).
Consistent with the hepatocyte
data, exon 12 contains an element
that regulates splicing of G6PD
pre-mRNA, and in this context the
element functions as an ESS inhibiting splicing.
To further confirm that intron 11
does not play a role in the inhibition
of splicing of G6PD pre-mRNA, we
compared the efficiency of splicing
between IVS 8-9, IVS 10-11, and
IVS 10,11,11 after 30, 60, 120, and
240 min of incubation with HeLa
nuclear extract (Fig. 4). For all in
vitro splicing substrates, spliced
products were detected after 30 min
of incubation and accumulated with
time (Fig. 4, A and B). The percentage of spliced product generated by
IVS 10,11,11 was similar to IVS
10-11 at all time points. In contrast,
splicing of IVS 8-9 was significantly
less at 30 and 60 min ( p ⬍ 0.001)
compared with IVS 10-11, indicating that the assay is sensitive enough
to detect small changes in spliced
product accumulation. The lack of
effect of intron 11 on splicing efficiency in the chimeric substrate
strengthens our conclusion that
exon 12 contains a splicing silencer.
Exon 12 Inhibits Splicing of G6PD
Pre-mRNA before the First Catalytic
Step—To corroborate the in vitro
splicing results indicating the presence of an ESS in exon 12, a spliceosome assembly assay was conducted. If the exon 12 regulatory
element has a dominant ESS, spliceosome assembly should be inhibited at an early step. The assembly of
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FIGURE 4. G6PD intron 11 is efficiently spliced in chimeric splicing substrates. A, the splicing substrates IVS 8-9, IVS 10-11, and IVS 10,11,11 described in Fig.
3 were used in in vitro splicing assays. The reactions were stopped after 30, 60, 120, and 240 min and resolved on 6% denaturing polyacrylamide gels. B,
quantification of the splicing efficiency of IVS 8-9, IVS 10-11, IVS 10,11,11 at 30, 60, 120, and 240 min. The splicing products were imaged and quantified using
phosphorimaging and ImageQuaNT software. The values are the PhosphorImager units normalized for the C content of the RNA. The percentage of spliced
mRNA was calculated as the ratio of the normalized PhosphorImager units of spliced mRNA divided by the sum of the amounts of unspliced plus spliced RNA.
Each bar represents mean ⫾ S.E. of n ⫽ 3 experiments for IVS 8-9 and IVS 10,11,11 and n ⫽ 5 experiments for IVS 10-11. The rate of increase of spliced product
accumulation for IVS 8-9 is significantly different from IVS 10-11 ( p ⬍ 0.001). Spliced product accumulations between IVS 10-11 and IVS 10,11,11 are not
significantly different. M, marker.

the spliceosome occurs stepwise and is characterized by the
interaction of multiple proteins and ribonuclear proteins with
the nascent transcript. These RNA and protein complexes are
as follows in order of formation: H, E, A, B, and C (15, 34, 44,
45). H is a nonspecific complex formed by interactions of the
pre-mRNA with multiple hnRNPs. The composition of this
complex can vary greatly in composition between different
RNAs but will include splicing regulatory proteins involved in
the formation of the catalytically competent spliceosome (46).
Its formation occurs even at 0 °C and does not require ATP.
Incubation of the pre-mRNA at 30 °C leads to formation of
complex E (45). In addition to splicing regulatory proteins, such
as the SR proteins and hnRNPs, complex E contains U1 snRNP
and the U2AF splicing factors at the 5⬘ and 3⬘ splice sites of the
intron, respectively (47). Complex A forms following the addition of ATP and involves binding of the splicing factor U2
snRNP to the branch point in the intron (48). Incorporation of
the U4/U5/U6 tri-snRNP leads to formation of complex B. Subsequently, after massive structural rearrangements, the catalytically activated spliceosome (complex C) forms, and the first
transesterification step of splicing occurs (15).
To determine if spliceosome assembly is inhibited by the ESS
present in exon 12, we analyzed the assembly of spliceosome
complexes on the splicing substrates. Four different 32P-labeled
in vitro splicing substrates were used. Three substrates con-
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tained G6PD sequences (Fig. 3A): IVS 8-9, IVS 10-11 (both are
spliced in the in vitro splicing assay), and IVS 11-12 (which was
not spliced in the in vitro splicing assay). The fourth substrate
was the human ␤-globin minigene containing exon 1, intron 1,
and exon 2 of human ␤-globin; it was included as a positive
control, because it is robustly spliced (29). In the absence of
ATP, only complexes H and E formed on all of the substrates
(Fig. 5, first lane of each panel). Upon the addition of ATP, we
observed the formation of complexes A and B ⫹ C on ␤-globin
mRNA (Fig. 5, first panel). Complexes H ⫹ E and B ⫹ C did not
resolve in 6% polyacrylamide gels. Formation of the A and B ⫹
C complexes on the ␤-globin mRNA was detected as early as 5
min (data not shown). Multiple spliceosome complexes were
also formed on the in vitro splicing substrates, IVS 8-9 and IVS
10-11; however, accumulation of complexes B ⫹ C was not
as rapid as in the case of ␤-globin (Fig. 5, second and third
panels). In contrast, a different pattern of complex formation
was observed with IVS 11-12 (Fig. 5, last panel). Complexes
H ⫹ E formed in the absence of ATP, although the mobility of
these complexes was faster than with other substrates (Fig. 5,
compare the first lane of each panel). The difference in the
mobility of the H ⫹ E complexes in IVS 11-12 is not simply due
to the smaller size of this splicing substrate (140 nt smaller than
IVS 8-9). IVS 8-9 and IVS 10-11 are 100 nt smaller than ␤-globin, and this did not result in a difference in the mobility of the
VOLUME 281 • NUMBER 45 • NOVEMBER 10, 2006
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FIGURE 5. The exon 12 ESS inhibits splicing of IVS 11-12 before the first catalytic reaction. Four 32P-labeled in vitro splicing substrates, ␤-globin, IVS 8-9, IVS
10-11, and IVS 11-12, were incubated with HeLa cell nuclear extracts under splicing conditions with or without ATP. At the indicated times, aliquots were
removed, and the spliceosome complexes were resolved on 4% nondenaturing polyacrylamide gels. The locations of bands corresponding to the spliceosome
complexes are indicated on the right.

H ⫹ E complexes. Upon the addition of ATP, complex A was
detected but was much less abundant compared with other
splicing substrates. Complexes B ⫹ C were not detected at the
early time points (10 and 20 min) with little or no accumulation
at the later times (30 and 60 min). These results suggest that the
ESS present in exon 12 inhibits the assembly of multiple proteins during spliceosome formation.
The altered mobility of complexes H ⫹ E and the decrease in
formation of complex A on IVS 11-12 suggested that inhibition
of splicing may occur at an early step in spliceosome assembly
such as assembly of complex E. Because complexes H and E are
not resolved in native polyacrylamide gels, we used 1.5% agarose gels to distinguish H and E complexes (35). Complex E was
readily detectable with the splicing substrate IVS 11-12 (Fig. 6).
Furthermore, the efficiency of complex E formation was similar
between IVS 8-9 and IVS 11-12. Thus, complexes H and E
formed on IVS 11-12, but the formation of complex A was
inhibited. The inhibition of the transition from complex A to B
is consistent with the presence of an ESS in the IVS 11-12 RNA
substrate.
The Addition of an SC35 Binding Site to IVS 11-12 Can Activate Splicing of Intron 11—If the regulatory sequence is only an
ESS, then elimination of this sequence from the RNA should
restore splicing. We tested this with two in vitro splicing substrates. The first eliminated all sequences 3⬘ of nucleotide 42 in
exon 12 (IVS 11-12 (42)) (Fig. 7A). This substrate was not
spliced (Fig. 7B, lane 2). We next eliminated only nucleotides
43–72 of exon 12 (IVS 11-12(⌬43–72)) (Fig. 7A). Elimination of
just the regulatory region failed to fully restore splicing (Fig. 7B,
NOVEMBER 10, 2006 • VOLUME 281 • NUMBER 45

lane 6). In some experiments, a faint band, corresponding to the
size of the spliced product was observed (lane 6, triangle). If the
element only contained an ESS, its elimination should restore
splicing. The fact that it did not could indicate that the regulatory element contains other splicing regulatory sites.
As a second approach to understanding the nature of the
exon 12 regulatory element, block mutations that abrogated
regulation by arachidonic acid were introduced into the IVS
11-12 splicing substrate. Splicing of the wild type substrate
occurred with typical low efficiency (19.3 ⫾ 1%; n ⫽ 3 experiments). Mutation of nt 43–52 (mutation 5 from Fig. 2) did not
alter splicing activity (18.7 ⫾ 4%; n ⫽ 3). Surprisingly, introduction of mutations 6 (nt 53– 62) and 7 (nt 63–72) decreased splicing efficiency by 50%. Splicing activity of IVS 11-12 mutation 6
was 10 ⫾ 2%, and splicing of IVS 11-12 mutation 7 was 9.3 ⫾ 1%
(n ⫽ 3). Although these are very small changes in spliced product formation, they are consistent with the regulatory element
having both negative and positive splicing regulatory activity.
ESEs are known to bind splicing co-activators that enhance
spliceosome formation by enhancing or stabilizing the interaction of U2 snRNP with the branch point during spliceosome
assembly (49). Transition from E complex to A complex
requires stable binding of U2 snRNP to the branch point site
(50). The decrease in complex A formation observed with IVS
11-12 (Fig. 5) suggests that binding of U2 snRNP to the branch
point is either attenuated or less stable compared with the other
in vitro splicing substrates.
To test if the addition of an SR protein-binding site can
induce splicing of IVS 11-12, we ligated an ESE onto exon 12.
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FIGURE 6. Complex E is efficiently formed on IVS 11-12. 32P-Labeled RNAs
for IVS 8-9 and IVS 11-12 were incubated with HeLa cell nuclear extracts under
splicing conditions but in the absence of ATP for 20 min at 0 or 30 °C. Spliceosome assembly was analyzed on 1.5% agarose gels. The locations of complexes H and E are indicated on the right.

Nucleotides 59 –78 of exon 2 of ␤-globin contain an SC35 binding site (UGCUGUU) (51); this site enhances U2 snRNP binding to the branch point (52). We added this region onto fulllength and truncated forms of IVS 11-12 to test if it can induce
splicing (IVS 11-12-SC35 and IVS 11-12(42)-SC35, respectively; Fig. 7A). The addition of the SC35 binding site induced splicing both in the presence and absence of the ESS (Fig. 7B, lanes 5
and 3, respectively). Of note, splicing of these substrates was
still only 50 – 60% as efficient as splicing of IVS 8-9, which does
not contain an ESS. Thus, the addition of an ESE can overcome
the inhibitory effect of the exon 12 ESS. In summary, these data
are consistent with the sequence from nucleotides 43–72 of
exon 12 containing a dominant ESS and a weak ESE.
Binding of hnRNPs and SR Proteins to the Exon 12 Regulatory
Element—ESE sequences bind members of the family of SR
proteins and ESS elements are known to bind hnRNPs. An RNA
affinity assay was used to determine the proteins that bind to
the RNA regulatory element. RNA oligonucleotides were
bound to adipic acid beads and incubated with HeLa nuclear
extract under splicing conditions. RNA was chemically synthesized to sequences 50 –79 (within the regulatory element),
70 –93 (outside the regulatory element), and a nonspecific oligomer (containing the sequence of the mutation) (Fig. 2A). The
oligomer representing the exon 12 regulatory sequences pulled
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FIGURE 7. The addition of an SC35 binding site to IVS 11-12 overcomes
the inhibitory effect of the exon 12 ESS on splicing of intron 11. A, schematic of modified IVS 11-12 in vitro splicing substrates with their calculated
sizes and the sizes of their products. White boxes, exon 11; lines between boxes,
intron 11; gray boxes, the sequence of exon 12; black boxes, nucleotides 50 –74
of ␤-globin exon 2 mRNA (GAUCUGUCCACUCCUGAUGCUGUUA) containing
the SC35 binding site (UGCUGUU). B, 6% denaturing polyacrylamide gels
were used to resolve the substrates and products of the in vitro splicing
assays. The asterisk indicates the spliced products for the substrates: IVS
11-12(42)-SC35 and IVS 11-12-SC35. The triangle indicates where a 139-nt
spliced product would run for IVS 11-12(⌬43–72). This figure represents a
single gel; the gap between lanes 1 and 2 is where lanes were removed from
the gel. M, marker.

down multiple proteins (Fig. 8A). Protein bands at 60 and 37
kDa were specifically detected with RNA representing the regulatory element and not with RNA to other regions of exon 12
(Fig. 8A, lane 1) or to the nonspecific sequences (Fig. 8A, lane
2). Bands marked with the asterisks were also detected with the
adipic acid beads in the absence of bound RNA (data not
shown). The band at 45 kDa was not uniformly observed in
multiple pull-down experiments. Binding of proteins to the
exon 12 regulatory region represented most of the protein
binding to the exon as detected using a UV cross-linking assay
(Fig. 8B). The regions of the gel containing bands at 60 and 37
kDa (band A and B, respectively) were excised and analyzed by
LC-MS/MS. Band A contained hnRNPs K, I, and L, and band B
VOLUME 281 • NUMBER 45 • NOVEMBER 10, 2006
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ulatory element (oligonucleotide
79 –93; Fig. 9A). As a negative control, the blots were probed for
hnRNP M, which was not detected
in the MS/MS identification.
hnRNP M was present in the HeLa
nuclear extract but did not bind
the nucleotide 43–72 regulatory
sequence (Fig. 9A). This indicates
that this assay detects specific
interactions between RNA-binding proteins and their binding
sequence.
hnRNPs L, K, and A2/B1 were
also present in nuclear extracts
from rat hepatocytes (Fig. 9A, right
panels, input) and were pulled down
by the exon 12 regulatory element
(Fig. 9A, right panels, oligonucleotide 43–72). Little or no binding of
these proteins was detected with the
sequence from 79 to 93, which is
outside the regulatory region.
hnRNP A2/B1 did not bind as
robustly in the hepatocyte nuclear
extract; the reason for this difference is not apparent. In contrast, the
hnRNP I amount in hepatocyte
nuclear extract was only 5% the
amount in HeLa nuclear extract.
Thus, little or no hnRNP I was
detected binding to the regulatory
element in hepatocyte nuclear
extract (Fig. 9A). The decrease in
hnRNP I may reflect tissue-specific
differences in the distribution of
FIGURE 8. Identification of proteins binding to exon 12 mRNA by RNA affinity purification. A, RNA oligonucleotides bound to adipic acid beads were mixed with 250 g of HeLa cell nuclear extract protein. The this protein or a weaker association
bound proteins were eluted from the RNA and separated by size on a polyacrylamide gel. The gel was stained of this protein with the regulatory
with SYPRO Ruby to image the bands and counterstained with colloidal Coomassie Blue to visualize the bands
prior to excising for MS/MS analysis. The boxes represent the regions excised from the gel. The asterisks are element in exon 12. Thus, although
bands detected with beads alone. A nonspecific oligonucleotide (NS) contained the sequences used in the it appears to be a binding protein, it
mutational analysis in Fig. 2 with A residues added to each end to make it 15 nt in length. B, exon 12 RNA was may not play a role in regulation of
in vitro transcribed and mixed with 5 g of HeLa cell nuclear extract protein. UV cross-linking was as described
under “Experimental Procedures.” The arrows marked A and B indicate bands of a size corresponding to what G6PD expression in hepatocytes.
was used in MS/MS analysis. C, proteins identified by MS/MS analysis in each of the excised bands. The acces- Once again, hnRNP M was present
sion numbers correspond to the human data base.
in the hepatocyte nuclear extract
but did not bind to the regulatory
contained hnRNPs A2/B1 (Fig. 8C). hnRNPs A2 and B1 are element or the nonregulatory sequence. Thus, hnRNPs L, K,
isoforms that differ by only 12 amino acids (53); thus, the spe- and A2/B1 are exon 12 mRNA-binding proteins in both HeLa
cific isoform would not be identified, because the software pro- cells and primary rat hepatocytes.
The results of the in vitro splicing assays (Fig. 7) are consistgram used did not search for low scoring peptides (⌬Cn ⬎ 0.1;
Xcorr ⬎ 1.9, 2.2, or 3.7 for the ⫹1, ⫹2, or ⫹3 charge states, ent with the exon 12 regulatory element also having ESE activity; if this sequence is present, SR proteins should bind to this
respectively).
The binding of these proteins to the exon 12 regulatory ele- region. To test for SR protein binding, Western analysis with an
ment was verified using specific antibodies. These hnRNPs antibody to total SR proteins was used against protein affinityhave been demonstrated to regulate RNA processing (10, 17, purified by the 43–72 oligonucleotide (Fig. 9B). SR proteins of
37, 46, 54). An oligonucleotide to the full regulatory element 80, 75, 37 (faint band), and 20 kDa bound to the element in
(nt 43–72) pulled down hnRNPs K, L, I, and A2/B1 from HeLa nuclear extract. No detectable binding was observed with
HeLa cell nuclear extract (Fig. 9A, left panels). In contrast, the RNA sequence outside the regulatory region (nt 79 –93). In
these proteins did not bind to sequences outside of the reg- nuclear extracts from rat hepatocytes, only proteins of ⬃75 kDa
NOVEMBER 10, 2006 • VOLUME 281 • NUMBER 45
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indicating that if an ESE is in this
regulatory element, it is weaker than
the ESS. Alternatively, the ESE and
ESS may be juxtaposed to exclude
binding of both proteins at the same
time.

DISCUSSION
Regulation of G6PD expression is
unique. Polyunsaturated fatty acids
and nutritional modifications, such
as starvation and refeeding, change
the accumulation of G6PD mRNA
by changes in the rate of pre-mRNA
splicing (2, 6). This regulation does
not involve changes in the rate of
transcription of the gene. In this
report, we present evidence that
regulation of G6PD splicing by polyunsaturated fatty acid involves an
ESS in exon 12 of the G6PD mRNA
(Figs. 1 and 2). This element is
located between nucleotides 43–72
of exon 12 and can inhibit splicing of
heterologous RNAs in intact cells
and out of its native context in substrates in the in vitro splicing assays
(Figs. 2 and 3). This silencer inhibits
spliceosome assembly during the
formation of complex A (Figs. 5 and
6). Furthermore, the regulatory element is bound by proteins either
associated with silencing or with
regulation of mRNA processing
(Figs. 8 and 9A). This is the first
report of an RNA element that is
FIGURE 9. hnRNPs K, L, and A2/B1 and SR proteins in nuclear extracts from HeLa cells and primary rat involved in the regulation of splicing
hepatocytes bind to the exon 12 regulatory element. Adipic acid beads linked with the indicated RNA by arachidonic acid, a polyunsatuoligonucleotides were mixed with 120 g of HeLa nuclear extract protein and 90 g of protein from rat rated fatty acid, and of the funchepatocyte nuclear extracts. Rat hepatocytes were incubated with insulin and arachidonic acid as described in
Fig. 1. Hepatocytes were harvested for extract preparation after 24 h of treatment. A, following elution of the tional characterization of an ESS
bound proteins with 150 l of buffer, the amount of eluate analyzed was as follows: 3 l for detection of involved in the regulation of constihnRNPs K and I, 1 l for detection of hnRNP L, and 3 l for hnRNP A2/B1 in HeLa or 10 l for hnRNP A2/B1 in rat
tutive splicing.
hepatocytes. Input was 2.4 and 3.0 g of protein for HeLa and hepatocytes, respectively. B, for detection of SR
True consensus sequences for
proteins, 15 and 20 l of eluted protein was used for HeLa cells and rat hepatocytes, respectively. These
experiments were repeated multiple times with two different nuclear extract preparation; the results of all ESSs remain to be established. The
experiments were similar. FA, arachidonic acid.
ESS in exon 12 does not match any
known ESSs when screened with
bound to the element. The absence of SRp20 binding may be available software (19, 21, 42). A similar observation has been
due to its lower abundance in rat hepatocyte nuclear extract made for other ESSs (17). Although we were not able to use
(Fig. 9B; compare inputs). Of note is that considerable more nuclear extracts prepared from primary rat hepatocytes for the
hnRNPs bound to the exon 12 regulatory element than SR pro- in vitro splicing studies because of the abundance of ribonucleteins. In order to detect SR protein binding to the regulatory ases, the results from in vitro splicing assays performed in HeLa
element, more protein was loaded onto the gel (e.g. for HeLa, 5 cell nuclear extracts are consistent with data obtained from
times more compared with hnRNP K and A2/B1 and 15 times transfection of G6PD pre-mRNA reporters into rat hepatocytes
more than hnRNP L). The amount of protein loaded into the in primary culture (Figs. 1 and 2). Both studies demonstrate a
input lanes was similar between the hnRNP and SR protein role for this element in inhibiting G6PD splicing.
Few splicing regulatory proteins have been described that
blots, indicating that the proteins are represented in these
extracts. The decreased binding of SR proteins to the exon 12 function in the inhibition of splicing. The detection of hnRNP L
regulatory element is consistent with our splicing data (Fig. 7), binding to the exon 12 element is consistent with it binding to
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the ESS of CD45 mRNA (17). hnRNP A2/B1 inhibits splicing of
human immunodeficiency virus RNA and binds an ESS within
this viral RNA (55). hnRNP I, also known as polypyrimidine
tract-binding protein, also functions in silencing splicing but
does so by binding to sequences in introns (10). In contrast, a
specific role for hnRNP K in the inhibition of splicing has not
been described. This protein appears to play multiple roles in
RNA processing, such that it may function a priori as a binding
partner for other nuclear proteins (54).
Splicing of RNA substrates containing exon 12 was inhibited
during complex A formation, which involves the recruitment
and stable interaction of U2 snRNP with the branch point in the
intron (45). The reduction in complex A formation may be
caused by a repressive effect of the exon 12 ESS on the strength
of binding of U2 or other splicing factors during the formation
of complex A. Activators such as the SR proteins can recruit
and or stabilize the interaction of U2 snRNP and thereby the
formation of a catalytically active spliceosome (52). The fact
that elimination of the exon 12 regulatory region failed to
restore robust splicing (IVS 11-12) (42) (Fig. 7), whereas the
addition of a strong ESE, capable of binding the ubiquitous SR
protein, SC35, restored splicing of this substrate (Fig. 7) is consistent with the need for an ESE in the exon. Juxtaposed ESE and
ESS sequences have been described in regulated splicing of a
number of mRNAs (23, 24). Our data are consistent with this
possibility. In this regard, the 30-nt sequence bound SR proteins that are known to interact with ESE sequences (Fig. 9B).
The ability of the sequence to bind to both splicing activators,
the SR proteins, and inhibitors, hnRNPs, supports the hypothesis of two sequences.
In the in vitro splicing assay, the ESS has a dominant inhibitory effect on splicing. In contrast, the abundance of G6PD
mRNA is enhanced in vivo by insulin and inhibited by arachidonic acid (e.g. Fig. 1). Thus, the activity of the regulatory element must also be regulated in response to these treatments. In
this regard, arachidonic acid stimulates silencing via this regulatory element, resulting in a decrease in pre-mRNA splicing
and thereby a decrease in G6PD mRNA abundance (2, 6) (Fig.
2). In contrast, insulin treatment must enhance splicing potentially via the binding of SR proteins. Insulin has been demonstrated to increase SRp40 phosphorylation and binding to an
ESE in the protein kinase C␤II mRNA (56). Insulin can also
regulate the interaction of hnRNP K with both mRNA and protein binding partners (57). Arachidonic acid inhibits insulin signaling in primary rat hepatocytes, and this inhibition is responsible for the decrease in G6PD mRNA in cells treated with
arachidonic acid (40). Therefore, we hypothesize that by attenuating insulin action, arachidonic acid may decrease splicing by
decreasing the activity of a splicing activator and thereby facilitating the preferential binding of a splicing inhibitor. Alternatively, insulin and arachidonic acid could more directly regulate
the binding and activity of proteins involved in silencing splicing irrespective of SR protein binding. Regulation of G6PD
expression by nutritional status is unique to liver and adipose
tissue. Furthermore, expression of G6PD in other cell types is
very low, consistent with silencing being the default pathway
(5). The binding of hnRNPs and SR proteins does not appear to
be regulated by arachidonic acid; however, the pull-down
NOVEMBER 10, 2006 • VOLUME 281 • NUMBER 45

approach may be insufficiently sensitive to detect these
changes, and/or the posttranslational modifications needed to
observe regulated binding might not be maintained in this
assay.
More research is still required to finely map the regulatory
element to distinguish ESS and ESE sequences and to define the
roles of hnRNPs and SR proteins in the regulation of G6PD
splicing. The lack of true consensus sequences for both ESEs
and ESSs means that these elements must be determined via
multiple approaches including functional assays. This work
establishes that ESSs can play a role in the splicing of constitutively spliced exons, and this role includes regulation of
pre-mRNA splicing in response to nutrient regulation.
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